| Name | NNK |
| Description | NNK is a nicotinic nitrosylated derivative. It activates ERK1/2 and PKCα, and activates Bcl2 phosphorylation at Ser70, as well as c-Myc at Thr58 and Ser62.It can be used to construct mouse models of lung cancer, as well as to induce proliferation and survival of human lung cancer cells. |
| In vitro | METHODS: CL1.0 cells were seeded in 96-well plates and treated with 0, 3 or 10 nM NNK for 24 h, followed by MTT to measure cell viability. Cells treated with 0 or 10 nM NNK for 24 h were collected and analyzed by RT-PCR. The expression of α3, α4, α5 and α7 was detected. GAPDH was used as internal control. Cells were also preincubated with -bungarotoxin (Bun, 10 nM) for 2 h and then stimulated with NNK (+, 10 nM) without (−) for 24 h. Study contactin-1 protein levels and mRNA expression.
RESULTS NNK increased contactin-1 protein levels and up-regulated contactin-1 mRNA in a dose-dependent manner, indicating that NNK may directly stimulate gene transcription and cause CL1.0 cells to exhibit weaker toxic effects. [3] |
| In vivo | METHODS: Female A/J mice (7 weeks old) were treated with eight consecutive doses of NNK (3 μmol per week) by intragastric gavage (i.g.) or intraperitoneal injection, and the carcinogenesis of the mice was observed. RESULTS After 26 weeks, all mice developed lung adenomas. [1] METHODS: F344 rats were administered subcutaneously three times a week for 20 weeks with a total dose of 702 mg. The carcinogenesis of the mice was observed after 12 months. RESULTS 67% of the rats developed lung cancer. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 20 mg/mL (96.51 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO : 60 mg/mL (289.53 mM), Sonication is recommended.
|
| Keywords | Bcl2 | inhibit | Inhibitor | Nicotine-nitrosated derivative | Lung cancer | NNK | c-Myc | Phosphorylation | Cell proliferation | Endogenous Metabolite |
| Inhibitors Related | 2,5-Di-tert-butylhydroquinone | Caffeic Acid | 5-LOX inhibitor | Diethylcarbamazine citrate | Setileuton | Phenidone | Resveratrol | Zileuton | PF-4191834 | 5-Aminosalicylic Acid | Malotilate | KKII5 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | NO PAINS Compound Library | Metabolism Compound Library | Human Endogenous Metabolite Compound Library Plus | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Human Metabolite Library | Anti-Cancer Active Compound Library |
United States
